Figure 2. (A) Percent viability of A549 (non-small-cell lung) and PC3 (prostate) human cancer cell lines (after 72 h) at 80 μM of compounds 1−7. (B) Dose−response of compound 7 against A549 (non-small-cell lung) and PC3 (prostate) human cancer cell lines (72 h). See also Supporting Information, Figure S4 and Table S1. 